Data Sheet (Cat.No.T1468)

TargetMol

Lornoxicam

Chemical Properties



CAS No. :	70374-39-9
Formula:	C13H10ClN3O4S2
Molecular Weight:	371.82
Storage:	Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	Lornoxicam (Chlortenoxicam) (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory, and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.
Targets(IC50)	Apoptosis,Endogenous Metabolite,NO Synthase,COX,Interleukin,Prostaglandin Receptor,TNF
In vitro	Lornoxicam is as effective as the opioid analgesics morphine, pethidine (meperidine) and tramadol in relieving postoperative pain following gynaecological or orthopaedic surgery, and as effective as other NSAIDs after oral surgery. Lornoxicam is also as effective as other NSAIDs in relieving symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute sciatica and low back pain. [1]
In vivo	Lornoxicam dose relatedly reduces the total number of c-Fos-LI neurons with the strongest effect corresponding to the 75% reduction for the highest dose of 9 mg/kg, and the 45% reduction for the low dose of 0.3 mg/kg. Lornoxicam (0.1, 0.3 mg/kg, 1 mg/kg, 3 mg/kg and 9 mg/kg, i.v.) significantly reduces the number of c-Fos-LI neurons in both superficial (24%, 33%, 53%, 54%, and 63% reduction, respectively) and deep (28%, 48%, 62%, 69% and 79% reduction, respectively) laminae of the dorsal horn of the spinal cord. [2] Lornoxicam reduces hyperalgesia with an effective dose that provides 50% inhibition (ED50) of 0.083 mg/kg, 3.9 mg/kg and 4.3 mg/kg respectively in a chronic rat model of arthritis. Lornoxicam significantly reduces the PGE2 level in paw exudate and the cerebrospinal fluid in rats. Lornoxicam 0.16 mg/kg, celecoxib 4 mg/kg and loxoprofen 2.4 mg/kg significantly reduces hyperalgesia to a similar extent in acute oedematous rats. [3]

Solubility Information

Solubility	DMSO: 10 mg/mL (26.89 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6895 mL	13.4474 mL	26.8947 mL
5 mM	0.5379 mL	2.6895 mL	5.3789 mL
10 mM	0.2689 mL	1.3447 mL	2.6895 mL
50 mM	0.0538 mL	0.2689 mL	0.5379 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Balfour JA, et al. Drugs,1996, 51(4), 639-657.
Buritova J, et al. Inflammopharmacology,1997, 5(4), 331-341.
Futaki N, et al. J Pharm Pharmacol,2009, 61(5), 607-614.
Berg J, et al. Inflamm Res. 1999, 48(7):369-79.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481